Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Luo ilmainen tunnus

Bioextrax

2,66 SEK

−0,75 %

Alle 1K seuraajaa

BIOEX

First North Stockholm

Industrial Goods & Services

Industrials

−0,75 %
−5,00 %
+4,72 %
−5,00 %
+6,07 %
+0,86 %
−59,93 %
−87,52 %
−30,65 %

Bioextrax was founded in 2014 based on research at Lund University. The company develops a technology platform for production of environmentally friendly materials based on microbiology. The platform includes two main technologies: 1) Production of polyhydroxyalkanoates (PHA) – a bio-based plastic that can replace fossil-based plastic, and 2) Feather hydrolysis – a technology that converts feathers into hydrolyzed protein for animal feed and keratin microfibers as additives in various materials.

Lue lisää
Markkina-arvo
126,62 milj. SEK
Vaihto
198,43 t. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Liikevaihto ja EBIT-%

Liikevaihto milj.

EBIT-% (oik.)

EPS ja Osinko

EPS (oik.)

Osinko %

Pörssikalenteri
20.5.
2026

Osavuosikatsaus Q1'26

21.5.
2026

Yhtiökokous '26

20.8.
2026

Osavuosikatsaus Q2'26

NäytäKaikki sisältötyypit
Kolmannen osapuolen analyysi

Bioextrax: Patience is a virtue - VH Corp

* Updates on Chematur, Konspec and the Candy producer * Lantmännen sparks hope for protein from feathers * We keep our fair value of SEK 3.7 per share Bioextrax reported an eventful Q4 2025, with EBIT of MSEK -5.0, slightly higher than expected. Cash...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: Advancements with the candy producer - VH Corp

* Regulatory evaluation successfully completed * Green light for the test panel to begin its work * We keep our fair value of SEK 3.7 per share Bioextrax recently communicated that the candy producer’s experts have completed their regulatory evaluation...

Bioextrax

Liity Inderesin yhteisöön

Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.

FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Luo ilmainen tunnus
Kolmannen osapuolen analyysi

Bioextrax: Financing secured for 2026 - VH Corp

* Rights issue extends financial runway * Revenue from Konspec expected by Q2 2026 * Adjustments lead to a fair value of SEK 3.7 (4.23) per share Bioextrax once again reported figures close to our estimates in its recent Q3 report. Both revenues and ...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: Which would you like to hear first? - VH Corp

* Production increase from 100 to 300 tons of PHA per year from Konspec * Project with the chemical company delayed, exclusivity removed * We keep our fair value of SEK 4.23 per share Good news and bad news caused some turbulence in the share price of...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: Still awaiting the potential to materialise - VH Corp

* Expecting agreements to materialise * Costs still in check * We keep our fair value to SEK 4.23 per share Bioextrax reported figures close to our estimates in its recent Q2 report. Revenues of MSEK 0.5 were slightly higher than expected, while costs...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: An exciting summer ahead - VH Corp

* Expecting agreements to materialise * Costs still in check * We keep our fair value to SEK 4.23 per share In the Q1 report 2025, CEO Edvard Hall updated on current projects. Before the Q2 report in August, we expect some of the collaborations to advance...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: Materialising opportunities - VH Corp

* Several agreements approaching * Costs in line with expectations * We have adjusted our fair value to SEK 4.23 per share The reported figures in Bioextrax's recent Q4 report were close to our estimates. With no significant sales forecast, costs came...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: High interest and steady progress - VH Corp

* High interest amid progression of the projects * The rights issue in Q4 added MSEK 14.1 * We keep our fair value of SEK 7.60 per share Bioextrax has received numerous inquiries from research institutes and companies since the summer. At the same time...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: Entering promising partnerships - VH Corp

[ingress] * Letter of intent with a leading chemical company * License agreement with Chematur Engineering regarding PHBV * We keep our fair value of SEK 7.60 per share During Q2, Bioextrax's project advanced. The company has entered into a license agreement...

Bioextrax
Kolmannen osapuolen analyysi

Bioextrax: Going from research to development - VH Corp

* Ökat fokus på affärsutveckling * En övertecknad emission gav 9 MSEK * Vi behåller det motiverade värdet om 7,60 SEK per aktie Under 2024 kommer Bioextrax att visa sin förmåga att omvandla lovande projekt till kommersiella avtal. Bolaget uppdaterade...

Bioextrax
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.